• Exchange: Xetra
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Intercept Pharmaceuticals Inc

+ Add to Watchlist

I4P:GR

224.688 EUR 0.431 0.19%

As of 09:34:46 ET on 08/27/2014.

Snapshot for Intercept Pharmaceuticals Inc (I4P)

Open: 227.010 Day's Range: 218.742 - 227.010 Volume: 0
Previous Close: 224.257 52wk Range: 32.741 - 355.675 1-Yr Rtn: +567.76%

Stock Chart for I4P

No chart data available.
  • I4P:GR 224.688
  • 1D
  • 1M
  • 1Y
224.257
Interactive I4P Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for I4P

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2014) -12.0370
Est. PEG Ratio -
Market Cap (M EUR) 4,767.42
Shares Outstanding (M) 21.22
30 Day Average Volume 71
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 11/14/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for I4P

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for I4P

Intercept Pharmaceuticals, Inc. manufactures and markets biopharmaceutical products. The Company focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. Intercept Pharmaceuticals serves customers throughout the United States.

Mark PruzanskiPresident/CEO/Co-FounderBarbara DuncanCFO/Treasurer/Secretary
Daniel P ReganChief Commercial OfficerRachel L McMinnChief Strategy Officer
More Company Profile & Key Executives for I4P

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil